STOCK TITAN

Scisparc - SPRC STOCK NEWS

Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.

Comprehensive Overview of SciSparc Ltd (SPRC)

SciSparc Ltd is a specialty clinical‐stage pharmaceutical company that leverages cutting‐edge cannabinoid technologies to develop innovative immunotherapy products and address central nervous system disorders. At its core, SciSparc focuses on the development of therapies derived from cannabinoid molecules, incorporating advanced biotechnology, immunotherapy, and clinical research methodologies. This dual‐focused enterprise operates across two distinct segments: one dedicated to clinical drug development and regulatory pathways, and another which drives the online sale of hemp-based consumable products.

Clinical-Stage Drug Development

The company’s primary business revolves around its clinical-stage drug development programs. SciSparc employs a portfolio based on both THC and non-psychoactive CBD compounds to create novel treatments for disorders such as Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus. Utilizing a rigorous, research-driven approach, the company undertakes controlled clinical trials designed to evaluate drug efficacy, safety, and tolerability. With its IND applications and approvals for advanced clinical programs, SciSparc demonstrates its commitment to meeting stringent regulatory standards and addressing unmet medical needs in its target therapeutic areas.

Innovative Technology and Intellectual Property

SciSparc’s market positioning is strengthened by its robust portfolio of patents and proprietary technologies. The company’s innovations in cannabinoid pharmaceuticals are not only geared towards improving treatment outcomes but also distinguishing its offerings from traditional therapies. By investing in advanced research platforms, including computational drug discovery and predictive artificial intelligence models, SciSparc is able to screen and identify promising molecular candidates for further development. This technological prowess, combined with a clear focus on regulatory compliance and scientific excellence, forms the backbone of its strategic differentiation.

Online Sales and Hemp-Based Consumer Products

In addition to its core clinical operations, SciSparc diversifies its business model through a reportable segment that manages the online sale of a wide range of hemp-derived products. These products, which include hemp gummies, oil capsules, topical gels, creams for beauty and hair treatments, and other nutraceutical items, are manufactured domestically in the United States. This segment not only leverages SciSparc’s expertise in cannabinoid science but also capitalizes on the growing consumer demand for hemp-based nutritional and wellness products.

Strategic Positioning in a Competitive Landscape

SciSparc operates in a competitive and dynamic landscape where rigorous clinical research, robust intellectual property protection, and diversified revenue streams are critical. The company’s dual approach—pursuing breakthrough therapies through detailed clinical trials while also serving a broad consumer market with hemp-based products—allows it to mitigate risk and explore multiple avenues for value creation. By maintaining adherence to high standards of scientific inquiry and regulatory diligence, SciSparc reinforces its position as a trusted and innovative entity within the pharmaceutical and nutraceutical industries.

Expertise, Experience, and Trustworthiness

The expertise demonstrated by SciSparc’s team of senior executives and scientists adds a further layer of credibility to its endeavors. The company’s rigorous research protocols, combined with its strategic investments in cutting-edge technology and regulatory expertise, underscore its commitment to scientific excellence and long-term value creation. This methodical, research-intensive approach not only builds trust among stakeholders but also serves as a foundation for advancing next-generation therapies in areas that have long presented clinical challenges.

Conclusion

In summary, SciSparc Ltd exemplifies a forward-thinking pharmaceutical enterprise that effectively blends innovative drug development with consumer-oriented online sales. Its robust portfolio in cannabinoid-based immunotherapies, supported by extensive intellectual property and strategic clinical trials, positions it uniquely within a competitive market landscape. Whether addressing central nervous system disorders or fulfilling the growing consumer demand for hemp products, SciSparc’s dual business model represents a comprehensive and balanced approach to modern pharmaceutical innovation.

Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) announced the launch of its new advanced facility in Ness-Ziona Science Park, Israel, through its joint venture MitoCareX Bio, aimed at developing anti-cancer drug candidates. This facility underscores the company’s commitment to addressing the global cancer crisis, which accounted for nearly 10 million deaths in 2020. MitoCareX Bio will focus on mitochondrial carriers critical for cell viability and is enhancing its computational drug discovery capabilities, building upon successful proof-of-concept research conducted in the U.K.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.63%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) has announced a $1 million share buyback program, aimed at enhancing shareholder value. The program will require court approval in Israel and is contingent upon the formal approval of financial statements for the six months ending June 30, 2022. The company is engaged in developing cannabinoid-based therapies targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder. This move reflects SciSparc's commitment to delivering shareholder returns amidst ongoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
buyback management
-
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) has announced the successful development of its drug candidate SCI-110 for an upcoming Phase IIb trial targeting Tourette Syndrome (TS). The company received ethics committee approvals from institutions in Germany and Israel for the study. SCI-110 aims to provide a safe treatment option for patients with limited alternatives. The multinational study will evaluate the drug's efficacy and safety in adults aged 18-65, focusing on tic severity changes. The trial's launch awaits further regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has received approval from the Soroka University Ethics Committee to conduct a clinical trial for its proprietary drug SCI-210, targeting Autism Spectrum Disorder (ASD). This trial aims to evaluate the safety, tolerability, and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, compared to CBD monotherapy in 60 children over 20 weeks. The approval marks a significant milestone for SciSparc in its pursuit of developing effective treatments for pediatric patients with limited options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
-
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) announced the appointment of Prof. Ciro Leonardo Pierri as a special advisor for MitoCareX Bio Ltd., its new joint venture focused on drug development for cancers and infectious diseases. Prof. Pierri, a biochemist from the University of Bari, Italy, brings expertise in structural biology and molecular modeling. The JV aims to explore mitochondrial carriers' roles in disease treatment, building on successful proof-of-concept experiments in the UK. SciSparc is engaged in cannabinoid-based drug development, targeting conditions like Tourette syndrome and Alzheimer’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) announced a review of potential strategic transactions aimed at maximizing shareholder value. The board is considering various options, including investments, acquisitions, partnerships, or licensing its technologies. CEO Oz Adler highlighted the company's strong cash position, allowing for exploration of external alternatives while continuing its existing business strategy. The firm remains focused on developing treatments for central nervous system disorders, including Alzheimer’s and Tourette syndrome, while adhering to FDA guidelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
management
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced positive initial pre-clinical results for a treatment for cocaine addiction using MEAI, a novel psychedelic molecule from Clearmind Medicine Inc. (CSE: CMND). The collaborative provisional patent application was filed to explore treatment potential based on SciSparc's CannAmide™ compound and Clearmind's MEAI. The trials indicated that MEAI could reduce cocaine's reward effects in rats, presenting a potential breakthrough in cocaine addiction treatment. The study was conducted by Professor Gal Yadid at Bar Ilan University.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has completed a $10 million private placement priced at-the-market, facilitated by Aegis Capital Corp. as the exclusive placement agent. The company is focused on developing cannabinoid-based pharmaceuticals, including SCI-110 for Tourette syndrome and SCI-160 for pain management. These projects aim to target various ailments such as Alzheimer's and autism. The private placement reflects investor confidence in SciSparc's innovative drug development pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Clearmind Medicine Inc. to file a provisional patent for a treatment targeting cocaine addiction. This involves a combination of SciSparc's CannAmide™ and Clearmind's MEAI, addressing the significant issue of cocaine addiction affecting over 1.3 million Americans. Current statistics highlight more than 350,000 hospital visits annually linked to cocaine use and around 16,000 overdose deaths. The collaboration aims to explore potential therapeutic solutions for addictions, with ongoing efforts to strengthen their partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced the closure of a private placement, securing approximately $10 million in gross proceeds from a single healthcare-focused institutional investor. The company issued 3,546,100 units at a price of $2.82 per unit, consisting of one ordinary share and two non-tradable warrants, each exercisable for an ordinary share at $2.57 for a total of 7,092,200 shares underlying the warrants. The warrants have a term of five years. Aegis Capital Corp. acted as the exclusive placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none

FAQ

What is the current stock price of Scisparc (SPRC)?

The current stock price of Scisparc (SPRC) is $0.3004 as of April 3, 2025.

What is the market cap of Scisparc (SPRC)?

The market cap of Scisparc (SPRC) is approximately 3.1M.

What is the primary focus of SciSparc Ltd?

SciSparc Ltd is primarily focused on developing cannabinoid-based immunotherapies to treat central nervous system disorders through rigorous clinical-stage drug development.

How does SciSparc generate its revenue?

The company generates revenue through two main segments: clinical-stage pharmaceutical research and development, and online sales of a variety of hemp-derived nutraceutical and wellness products.

What types of disorders is SciSparc targeting?

SciSparc is targeting several CNS disorders including Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus, among other conditions.

How does SciSparc differentiate itself in the pharmaceutical industry?

SciSparc differentiates itself through its proprietary portfolio of cannabinoid-based technologies, its advanced clinical trials, and its dual business model that spans both innovative drug development and consumer hemp products.

What role do patents and proprietary technologies play at SciSparc?

The company's extensive portfolio of patents and proprietary technologies underscores its commitment to innovation and regulatory compliance, providing a competitive edge in drug discovery and development.

How does SciSparc manage regulatory compliance?

SciSparc adheres to strict regulatory standards by conducting controlled clinical trials, obtaining IND approvals, and ensuring that its hemp-based products are manufactured under stringent quality controls in the United States.

What market segments does SciSparc serve?

SciSparc serves both the pharmaceutical market with its drug development programs and the consumer market through its online distribution of hemp-based nutraceutical and wellness products.

How experienced is the management team at SciSparc?

SciSparc is led by a team of experienced senior executives and scientists, whose expertise in fields such as clinical research, regulatory affairs, and biotechnology supports the company’s innovative approach and enhances its trustworthiness.
Scisparc

Nasdaq:SPRC

SPRC Rankings

SPRC Stock Data

3.14M
10.83M
0%
1.21%
0.62%
Biotechnology
Healthcare
Link
Israel
Tel Aviv